Tobam Makes New $606,000 Investment in Amgen Inc. $AMGN

Tobam acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,851 shares of the medical research company’s stock, valued at approximately $606,000.

A number of other institutional investors have also recently made changes to their positions in the company. Anfield Capital Management LLC grew its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC increased its stake in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after acquiring an additional 55 shares during the last quarter. Board of the Pension Protection Fund purchased a new stake in shares of Amgen during the 4th quarter worth approximately $26,000. Manning & Napier Advisors LLC raised its holdings in shares of Amgen by 49.2% during the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC purchased a new stake in shares of Amgen during the 4th quarter worth approximately $33,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN opened at $337.60 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock’s fifty day moving average is $340.71 and its two-hundred day moving average is $345.76. The company has a market capitalization of $182.21 billion, a P/E ratio of 23.49, a PEG ratio of 3.39 and a beta of 0.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the business earned $4.90 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Analysts forecast that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.85% of the stock is currently owned by insiders.

Analyst Ratings Changes

AMGN has been the subject of a number of recent research reports. Canaccord Genuity Group assumed coverage on shares of Amgen in a report on Monday, April 20th. They issued a “hold” rating and a $366.00 target price for the company. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a research note on Friday, June 5th. Mizuho increased their price objective on shares of Amgen from $295.00 to $303.00 and gave the company a “neutral” rating in a research report on Tuesday, June 16th. Guggenheim dropped their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. Finally, Jefferies Financial Group initiated coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, fifteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $354.42.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.